Tarsons Products Ltd

- The company anticipates peak debt on a standalone basis not exceeding INR 350 crores. - Total debt on consolidation (including subsidiaries) is expected to peak around INR 425 crores to INR 450 crores. - There is no explicit mention of plans for new equity fundraising in the discussed pages. - The company is focused on disciplined loan repayment to manage debt levels. - Ongoing capital expenditures are being managed with existing financial arrangements; no clear indication of additional external fundraising through debt or equity at this time.

- Total capex planned between INR550 crores to INR650 crores, covering Panchla, Amta, and existing plants. - Panchla facility focused on capacity expansion for existing products and launching new products like cell culture products. - Amta facility includes radiation and sterilization plant, with some manufacturing of existing products starting soon. - Capex timeline extended due to inflation and foreign exchange fluctuations; expected to be fully commissioned by Q4 FY26. - Peak asset turnover estimated at 0.7 to 0.8 on gross block level. - Ramp-up for new products expected over 3 to 5 years; existing product expansion over 2 to 3 years. - No plans to shut down old facilities; all will operate concurrently. - Strategic investment aims at reducing dependency on sole vendors (e.g., in radiation) and increasing operating leverage through sterile goods production.

- Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years. - Capacity expansion underway (Panchla and Amta facilities) targeting peak revenue potential of INR350-400 crores, with INR100-125 crores from existing products and the rest from new products. - Ramp-up timeline for full utilization is estimated at 3 to 5 years, with gradual market penetration and customer validation. - Export market inquiries are strong, with efforts to increase wallet share in both domestic and international markets. - Domestic market growth is challenged by high competition and price sensitivity; however, new products and increasing brand recall are expected to support incremental revenue. - No planned price cuts; growth is expected to be volume-driven without margin erosion. - Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities.

- Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports. - Capacity expansion at Panchla and Amta facilities to be fully ramped by Q4 FY26, enabling increased production and revenue potential (~INR350-400 crores peak revenue). - Ramp-up timelines for capacity expansion and new products projected at 3-5 years. - EBITDA margins expected to improve due to higher revenue, favorable product mix, and operating leverage. - PAT margins currently affected by higher depreciation but expected to normalize once facilities fully commissioned. - Operating cash flow has shown significant improvement, doubling in H1 FY26 compared to the prior year. - No explicit EPS guidance provided, but sustained volume growth and margin expansion suggest positive earnings trajectory going forward. - External challenges like U.S. tariffs and global freight issues may impact near-term growth, but management remains optimistic.

- Tarsons is experiencing a healthy and growing order book across global markets, including the U.S. and other international regions. - Some orders are delayed or pending due to capacity constraints and ongoing machine commissioning. - Management is optimistic about export growth by the end of the year, expecting to overcome current shipment delays caused by factors like non-issuance of Bills of Lading. - Existing customers continue to place orders, with no loss of clients despite tariff challenges. - There is a steady flow of inquiries for both existing and new products, especially for ODM contracts, indicating potential future order additions. - The company expects gradual ramp-up in order fulfillment as new capacities (Amta and Panchla facilities) come online within 3 to 5 years.